Simvastatin-dependent apoptosis in Hodgkin's lymphoma cells and growth impairment of human Hodgkin's tumors in vivo

Haematologica

Volumn 92, Issue 5, 2007, Pages 682-685

  Von Tresckow, Bastian ^a   Von Strandmann, Elke Pogge ^b   Sasse, Stephanie ^b   Tawadros, Samir ^b   Engert, Andreas ^b   Hansen, Hinrich P ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b NONE

Author keywords

Apoptosis; Growth control; Lymphoma; Statins

Indexed keywords

CASPASE; GGTI 298; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; SIMVASTATIN; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; DRUG DERIVATIVE; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; GERANYLGERANYLTRANSFERASE TYPE I; GERANYLGERANYLTRANSFERASE TYPE-I; METHIONINE; TRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG MEGADOSE; GROWTH INHIBITION; HODGKIN DISEASE; HUMAN; HUMAN CELL; LOW DRUG DOSE; LYMPHOMA CELL LINE; MOUSE; NONHUMAN; PRENYLATION; ANIMAL; CANCER TRANSPLANTATION; CELL CULTURE; CELL STRAIN K 562; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; PATHOLOGY; PROTEIN PROCESSING;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HODGKIN DISEASE; HUMANS; K562 CELLS; METHIONINE; MICE; NEOPLASM TRANSPLANTATION; PROTEIN ISOPRENYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIMVASTATIN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34447295155     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11020     Document Type: Article

References (20)

1. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005;5:930-42.
2. Fortuny J, de Sanjose S, Becker N, Maynadie M, Cocco PL, Staines A, et al. Statin use and risk of lymphoid neoplasms: results from the European Case-Control Study EPILYMPH. Cancer Epidemiol Biomarkers Prev 2006;15:921-5.
3. Mesa RA. Tipifarnib: farnesyl transferase inhibition at a crossroads. Expert Rev Anticancer Ther 2006; 6: 313-9.
4. Klimka A, Barth S, Drillich S, Wels W, van Snick J, Renauld JC, et al. A deletion mutant of Pseudomonas exotoxin-A fused to recombinant human interleukin-9 (rhIL-9-ETA') shows specific cytotoxicity against IL-9-receptor-expressing cell lines. Cytokines Mol Ther 1996;2:139-46.
5. von Kalle C, Wolf J, Becker A, Sckaer A, Munck M, Engert A, et al. Growth of Hodgkin cell lines in severely combined immunodeficient mice. Int J Cancer 1992;52:887-91.
6. Boll B, Hansen H, Heuck F, Reiners K, Borchmann P, Rothe A, et al. The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis. Blood 2005;106:1839-42.
7. Soldani C, Scovassi AI. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 2002;7:321-8.
8. van de Donk NW, Schotte D, Kamphuis MM, van Marion AM, van Kessel B, Bloem AC, et al. Protein geranylgeranylation is critical for the regulation or survival and proliferation of lymphoma tumor cells. Clin Cancer Res 2003;9:5735-48.
9. Katano H, Pesnicak L, Cohen JI. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci USA 2004;101:4960-5.
10. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996;2:483-91.
11. Holstein SA, Knapp HR, Clamon GH, Murry DJ, Hohl RJ. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother Pharmacol 2006;57:155-64.
12. Clutterbuck RD, Millar BC, Powles RL, Newman A, Catovsky D, Jarman M, et al. Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice. Br J Haematol 1998;102:522-7.
13. van der Spek E, Bloem AC, van de Donk NW, Bogers LH, van der Griend R, Kramer MH, et al. Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. Haematologica 2006; 91: 542-5.
14. Cohen JI. HMG CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphoma. Br J Cancer 2005;92:1593-8.
15. Feleszko W, Mlynarczuk I, Balkowiec-Iskra EZ, Czajka A, Switaj T, Stoklosa T, et al. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin Cancer Res 2000;6:2044-52.
16. Morgan MA, Sebil T, Aydilek E, Peest D, Ganser A, Reuter CW. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells. Br J Haematol 2005; 130: 912-25.
17. Xia Z, Tan MM, Wong WW, Dimitroulakos J, Minden MD, Penn LZ. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 2001;15:1398-407.
18. Bolick SC, Landowski TH, Boulware D, Oshiro MM, Ohkanda J, Hamilton AD, et al. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia 2003;17:451-7.
19. Martin NE, Brunner TB, Kiel KD, DeLaney TF, Regine WF, Mohiuddin M, et al. A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin Cancer Res 2004;10:5447-54.
20. McCormack P, Macpherson M, Wilson D, Lindsay A, Parry T, Holt A, et al. Pharmacokinetic characterization of the novel oral prenyl transferase inhibitor AZD3409: The first analysis in healthy male volunteers. J Clin Oncol (Meeting Abstracts) 2004;22 Suppl 14:3172-5.